MarginsXMarginsX
Home › Markets › LGNDZ

Ligand Pharmaceuticals Inc (LGNDZ)

LGNDZ is quoted over the counter, not listed on an exchange. Ligand Pharmaceuticals Inc files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.

Close
No daily closes stored yet
No new price since Oct 30, 2026: the price source has sent no bar for 11 sessions
1-year return
No daily closes stored yet
Market cap
The company also trades on Nasdaq as LGND; this OTC line is another class or a foreign line, so its cap is not computed
P/E and P/S
Needs a market cap · Needs a market cap
On trailing twelve months to September 30, 2026 (10-Q)

Profile

FieldValue
TickerLGNDZ, quoted over the counter
SEC CIK0000886163
OTC Markets tierPink (price source, 2026-11-13)
SEC industry codePharmaceutical Preparations
Business addressPalm Beach Gardens, FL
Incorporated inDE

Warning signs

Cash runway
Cash-flow positive
$56.0M cash at September 30, 2026
Share count, 1 year
+1.6%
2025-11-04 to 2026-10-27 · +14.7% over 3 years
Going-concern doubt
No
10-Q filed October 30, 2026
Insider net buying, 12 months
-$33.3M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-30
Cash and burn$56.0M cash; operating cash flow $22.8M a quarter.Report 2026-09-30
Shares outstanding20,002,986 (2026-10-27); 19,681,720 a year earlier; 17,435,958 three years earlier.Cover page 2026-10-27
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-02-27
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Diego, California, United StatesPCAOB Form AP 2026-03-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $33.3M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$78.7M-$28.5M-$27.6M$56.0M$1.1B$253.8M10-Q 2026-10-30
Q2 2026
2026-06-30
$63.7M$48.5M$24.0M$1.0B$1.1B$290.5M10-Q 2026-08-07
Q1 2026
2026-03-31
$51.7M-$13.3M$48.7M$115.1MNo debt tags$274.5M10-Q 2026-05-08
Q4 2025
2025-12-31
$59.7M$44.8M$45.9M$174.9MNo debt tags$268.1M10-K 2026-02-27
Q3 2025
2025-09-30
$115.5M$117.3M$13.1M$139.4MNo debt tags$251.2M10-Q 2026-10-30
Q2 2025
2025-06-30
$47.6M$4.8M$15.8M$67.7MNo debt tags$187.6M10-Q 2026-08-07
Q1 2025
2025-03-31
$45.3M-$42.5M-$25.4M$48.0MNo debt tags$181.5M10-Q 2026-05-08
Q4 2024
2024-12-31
$42.8M-$31.1M$28.5M$72.3MNo debt tags$167.1M10-K 2026-02-27

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-02-27
Latest annual report10-K2026-02-27
Latest quarterly / interim10-Q2026-10-30
Latest current report8-K2026-10-29
Latest proxyDEFA14A2026-05-18

Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.

The full dossier has every filing, quarterly and annual financials, the health record and a price chart.

Open the full dossier